Report ONRELTEA bad reactions to Canada Vigilance Program


Users of ONRELTEA in Canada who have bad reactions or `adverse events’ related to using this newly approved product are reminded in the ONRELTEA Product Monograph to report these events. The body responsible for supervising prescription drugs is the Canada Vigilance Program.

The Brimonidine based topical which is available in the US as Mirvaso has recently become available in Canada and is called ONRELTEA by Galderma.

It is difficult to gauge what proportion of users have experienced adverse reactions to Mirvaso, but samples of online reports seem to suggest higher bad reactions than reported in the Phase 3 Trials for Mirvaso.

Canadian users of ONRELTEA who suffer from adverse events should report their experiences as indicated below.

ONRELTEA Product Monograph


You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:

Fax toll-free to 1-866-678-6789, or Mail to:

Canada Vigilance Program
Health Canada
Postal Locator 0701D
Ontario K1A 0K9

Postage paid labels, Canada Vigilance Reporting Form and the adverse reaction reporting guidelines are available on the MedEffect™ Canada Web site at

User Comments

Also feel free to let others know how you are going with ONRELTEA at the ONRELTEA User Reviews page.

Related Articles

About the Author

About the Author: David Pascoe started the Rosacea Support Group in October 1998. .

Follow Rosacea Support

Subscribe via RSS Feed

Leave your comment here


Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.